Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy

被引：1

作者：

Kim, Tae Min ^{[1
]}

Girard, Nicolas ^{[2
]}

Low, Grace Kah Mun ^{[3
]}

Zhuo, Jianmin ^{[4
]}

Yu, Dae Young ^{[5
]}

Yang, Yishen ^{[4
]}

Murota, Maiko ^{[6
]}

Lim, Cindy Thiow Koon ^{[7
]}

Kleinman, Nora J. ^{[8
]}

Cho, Byoung Chul ^{[9
]}

机构：

[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[2] Inst Curie, Inst Thorax Curie Montsouris, Paris, France

[3] Johnson & Johnson Int Singapore Pte Ltd, Med Affairs, Janssen Asia Pacif Med Affairs, Singapore, Singapore

[4] Janssen China Res & Dev, Stat & Decis Sci, Beijing, Peoples R China

[5] Janssen Asia Pacific, Real World Evidence, Seoul, South Korea

[6] Janssen Res & Dev, Global Dev, Med Affair Operat, Tokyo, Japan

[7] IQVIA Solut Asia Pte Ltd, Real World Solut, Singapore, Singapore

[8] IQVIA Hong Kong, Real World Solut, Kwai Fong, Hong Kong, Peoples R China

[9] Yonsei Univ, Dept Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

来源：

ACTA ONCOLOGICA | 2023年

关键词：

CHRYSALIS trial; external control; LC-SCRUM-Asia; amivantamab; EGFR exon 20 insertions; MOLECULAR HETEROGENEITY; CLINICAL-RESPONSE; ADENOCARCINOMAS;

D O I：

10.1080/0284186X.2023.2254479

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with EGFR Exon 20ins. This study compared the effectiveness of amivantamab to real-world systemic anti-cancer therapies in Japan. Patients and methods: External control patients were selected by applying CHRYSALIS eligibility to Japanese patients from LC-SCRUM-Asia. External control patients were included for every qualifying line of therapy after platinum-based chemotherapy. Propensity score weighting was applied to external control patients to adjust for differences in baseline characteristics. Outcomes were compared between external control patients, and all and Asian-only CHRYSALIS patients using weighted Cox proportional hazards regression models for progression-free survival (PFS), time to next therapy (TTNT), and overall survival (OS), and generalized estimating equations with repeated measurements for overall response rate (ORR). Results: One hundred fifteen CHRYSALIS and 94 external control patients were identified. Compared to external control patients, amivantamab-treated patients had significantly longer OS (median OS 19.88 vs 14.09months, HR [95% CI] 0.59 [0.40-0.88]), PFS (median PFS 6.74 vs 4.73months, HR 0.59 [0.45-0.78]), TTNT (median TTNT 12.16 vs 5.09months, HR 0.39 [0.29-0.53]), and significantly higher ORR (41.7% vs 14.1%). Analyses of amivantamab-treated Asian patients (n=61) showed similar clinical benefits. Conclusion: In the absence of clinical evidence from randomized clinical trials, this study reflects the benefit of amivantamab after platinum-based chemotherapy for advanced non-small cell lung cancer patients harboring EGFR Exon 20ins, compared to current real-world therapies.

引用

页码：1689 / 1697

页数：9

共 43 条

[1] EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics [J].

Arcila, Maria E. ;

Nafa, Khedoudja ;

Chaft, Jamie E. ;

Rekhtman, Natasha ;

Lau, Christopher ;

Reva, Boris A. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) :220-229

[2] EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP) [J].

Cardona, Andres F. ;

Rojas, Leonardo ;

Lucia Zatarain-Barron, Zyanya ;

Freitas, Helano C. ;

Granados, Sara T. ;

Castillo, Omar ;

Oblitas, George ;

Corrales, Luis ;

Castro, Christian D. ;

Ruiz-Patino, Alejandro ;

Martin, Claudio ;

Angelina Perez, Maria ;

Gonzalez, Lisde ;

Chirinos, Luis ;

Vargas, Carlos ;

Carranza, Hernan ;

Otero, Jorge ;

Rodriguez, July ;

Rodriguez, Jenny ;

Archila, Pilar ;

Lema, Mauricio ;

Acosta Madiedo, Jose ;

Karachaliu, Niki ;

Wills, Beatriz ;

Pino, Luis E. ;

de Lima, Vladimir ;

Rosell, Rafael ;

Arrieta, Oscar .

LUNG CANCER, 2018, 125 :265-272

[3] The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer [J].

Chansky, Kari ;

Detterbeck, Frank C. ;

Nicholson, Andrew G. ;

Rusch, Valerie W. ;

Vallieres, Eric ;

Groome, Patti ;

Kennedy, Catherine ;

Krasnik, Mark ;

Peake, Michael ;

Shemanski, Lynn ;

Bolejack, Vanessa ;

Crowley, John J. ;

Asamura, Hisao ;

Rami-Porta, Ramon .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (07) :1109-1121

[4] Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations [J].

Chen, Dan ;

Song, Zhengbo ;

Cheng, Guoping .

ONCOTARGETS AND THERAPY, 2016, 9 :4181-4186

[5] Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions [J].

Choudhury, Noura J. ;

Schoenfeld, Adam J. ;

Flynn, Jessica ;

Falcon, Christina J. ;

Rizvi, Hira ;

Rudin, Charles M. ;

Kris, Mark G. ;

Arcila, Maria E. ;

Heller, Glenn ;

Yu, Helena A. ;

Ladanyi, Marc ;

Riely, Gregory J. .

CLINICAL CANCER RESEARCH, 2021, 27 (10) :2920-2927

[6]

Collins LG, 2007, AM FAM PHYSICIAN, V75, P56

[7]

Ferlay J, 2010, BREAST CANCER EPIDEMIOLOGY, P1, DOI 10.1007/978-1-4419-0685-4_1

[8] Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions [J].

Floc'h, Nicolas ;

Martin, Matthew J. ;

Riess, Jonathan W. ;

Orme, Jonathan P. ;

Staniszewska, Anna D. ;

Menard, Ludovic ;

Cuomo, Maria Emanuela ;

O'Neill, Daniel J. ;

Ward, Richard A. ;

Finlay, M. Raymond V. ;

McKerrecher, Darren ;

Cheng, Mingshan ;

Vang, Daniel P. ;

Burich, Rebekah A. ;

Keck, James G. ;

Gandara, David R. ;

Mack, Philip C. ;

Cross, Darren A. E. .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) :885-896

[9] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors [J].

Gazdar, A. F. .

ONCOGENE, 2009, 28 :S24-S31

[10]

Goto K., 2017, Annals Oncol, V28, pix5, DOI [10.1093/annonc/mdx570.001, DOI 10.1093/ANNONC/MDX570.001]

← 1 2 3 4 5 →